{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"82.2","upperLimit":"99.9","value":"96.6"},{"groupId":"OG001","lowerLimit":"85.6","upperLimit":"98.4","value":"94.1"},{"groupId":"OG002","lowerLimit":"63.1","upperLimit":"100.0","value":"100.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"8"}],"units":"Participants"}],"description":"VGPR or better response rate was defined as the percentage of participants who achieved VGPR or complete response (CR) (including stringent complete response \\[sCR\\]) according to the IMWG criteria during or after the study treatment. VGPR: Serum and urine component detectable by immunofixation but not on electrophoresis, or \\>= 90% reduction in serum M-protein plus urine M-protein level less than (\\<) 100 mg/24 hour; CR: negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \\<5% PCs in bone marrow; sCR: CR in addition to having a normal free light chain (FLC) ratio and an absence of clonal cells in bone marrow by immunohistochemistry, immunofluorescence, 2-4 color flow cytometry.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 milligrams per meter square (mg/m\\^2) intravenous (IV) infusion and fludarabine 30 mg/m\\^2 as IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received target dose of JNJ-68284528 0.75\\*10\\^6 chimeric antigen receptor T (CAR-T) cells per kilogram (cells/kg) (range: 0.5-1.0\\*10\\^6 CAR-positive viable cells/kg) as IV infusion.","id":"OG000","title":"Phase 1b (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG001","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG002","title":"Phase 2 (Japan Population)"}],"paramType":"NUMBER","populationDescription":"mITT analysis Set included all participants who received a JNJ-68284528 infusion at the targeted RP2D dose level. Here, N (number of participants analyzed) signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre dose (Day 1) up to 45.2 months","title":"Phase 1b and Phase 2: Very Good Partial Response (VGPR) or Better Response Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}